Novo Nordisk Revenue 2010-2024 | NVO
Novo Nordisk annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Novo Nordisk revenue for the quarter ending September 30, 2024 was $10.511B, a 22.58% increase year-over-year.
- Novo Nordisk revenue for the twelve months ending September 30, 2024 was $39.373B, a 27.63% increase year-over-year.
- Novo Nordisk annual revenue for 2023 was $33.724B, a 34.59% increase from 2022.
- Novo Nordisk annual revenue for 2022 was $25.057B, a 11.85% increase from 2021.
- Novo Nordisk annual revenue for 2021 was $22.401B, a 15.18% increase from 2020.
Novo Nordisk Annual Revenue
(Millions of US $) |
| 2023 |
$33,724 |
| 2022 |
$25,057 |
| 2021 |
$22,401 |
| 2020 |
$19,448 |
| 2019 |
$18,291 |
| 2018 |
$17,099 |
| 2017 |
$16,967 |
| 2016 |
$16,611 |
| 2015 |
$16,060 |
| 2014 |
$15,834 |
| 2013 |
$14,884 |
| 2012 |
$13,483 |
| 2011 |
$12,400 |
| 2010 |
$10,836 |
| 2009 |
$9,567 |
Novo Nordisk Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$10,511 |
| 2024-06-30 |
$9,821 |
| 2024-03-31 |
$9,515 |
| 2023-12-31 |
$9,526 |
| 2023-09-30 |
$8,575 |
| 2023-06-30 |
$7,933 |
| 2023-03-31 |
$7,690 |
| 2022-12-31 |
$6,652 |
| 2022-09-30 |
$6,165 |
| 2022-06-30 |
$5,901 |
| 2022-03-31 |
$6,338 |
| 2021-12-31 |
$5,916 |
| 2021-09-30 |
$5,650 |
| 2021-06-30 |
$5,356 |
| 2021-03-31 |
$5,480 |
| 2020-12-31 |
$5,157 |
| 2020-09-30 |
$4,856 |
| 2020-06-30 |
$4,432 |
| 2020-03-31 |
$5,003 |
| 2019-12-31 |
$4,798 |
| 2019-09-30 |
$4,511 |
| 2019-06-30 |
$4,523 |
| 2019-03-31 |
$4,458 |
| 2018-12-31 |
$3,934 |
| 2018-09-30 |
$4,331 |
| 2018-06-30 |
$4,388 |
| 2018-03-31 |
$4,446 |
| 2017-12-31 |
$4,446 |
| 2017-09-30 |
$4,205 |
| 2017-06-30 |
$4,236 |
| 2017-03-31 |
$4,080 |
| 2016-12-31 |
$4,284 |
| 2016-09-30 |
$4,131 |
| 2016-06-30 |
$4,171 |
| 2016-03-31 |
$4,025 |
| 2015-12-31 |
$4,234 |
| 2015-09-30 |
$3,995 |
| 2015-06-30 |
$4,010 |
| 2015-03-31 |
$3,820 |
| 2014-12-31 |
$4,161 |
| 2014-09-30 |
$3,960 |
| 2014-06-30 |
$3,975 |
| 2014-03-31 |
$3,737 |
| 2013-12-31 |
$3,957 |
| 2013-09-30 |
$3,643 |
| 2013-06-30 |
$3,746 |
| 2013-03-31 |
$3,539 |
| 2012-12-31 |
$3,653 |
| 2012-09-30 |
$3,336 |
| 2012-06-30 |
$3,364 |
| 2012-03-31 |
$3,130 |
| 2011-12-31 |
$3,211 |
| 2011-09-30 |
$3,093 |
| 2011-06-30 |
$3,088 |
| 2011-03-31 |
$2,878 |
| 2010-12-31 |
$2,978 |
| 2010-09-30 |
$2,905 |
| 2010-06-30 |
$2,721 |
| 2010-03-31 |
$2,451 |
| 2009-12-31 |
$2,586 |
| 2009-09-30 |
$2,483 |
| 2009-06-30 |
$2,379 |
| 2009-03-31 |
$2,223 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$479.942B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
